In summary, the FGF-21 agonist, the FGF-19 analog, and the CCR2/CCR5 antagonist have great therapeutic potential for the treatment of MASH and MASLD. This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatohepatitis.